170 related articles for article (PubMed ID: 31387552)
1. Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: a case report.
Kim CY; Kim N; Choung HK; In Khwarg S
BMC Cancer; 2019 Aug; 19(1):774. PubMed ID: 31387552
[TBL] [Abstract][Full Text] [Related]
2. Effect of early adverse events resulting in ado-trastuzumab emtansine dose adjustments on survival outcomes of HER2+ advanced breast cancer patients.
Tang E; Rowland A; McKinnon RA; Sorich MJ; Hopkins AM
Breast Cancer Res Treat; 2019 Nov; 178(2):473-477. PubMed ID: 31399933
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy.
Molinelli C; Parisi F; Razeti MG; Arecco L; Cosso M; Fregatti P; Del Mastro L; Poggio F; Lambertini M
Expert Rev Anticancer Ther; 2021 Mar; 21(3):241-250. PubMed ID: 33245671
[No Abstract] [Full Text] [Related]
4. Liver sinusoidal obstruction syndrome associated with trastuzumab emtansine treatment for breast cancer.
Duret-Aupy N; Lagarce L; Blouet A; Kettani S; Conte C; Bourneau-Martin D; Drablier G; Umlil A; Briet M
Therapie; 2019 Dec; 74(6):675-677. PubMed ID: 31023619
[No Abstract] [Full Text] [Related]
5. Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate.
Yamashita-Kashima Y; Yoshimura Y; Fujimura T; Shu S; Yanagisawa M; Yorozu K; Furugaki K; Higuchi R; Shoda J; Harada N
Cancer Chemother Pharmacol; 2019 Apr; 83(4):659-671. PubMed ID: 30659304
[TBL] [Abstract][Full Text] [Related]
6. Combination of Trastuzumab Emtansine and Stereotactic Radiosurgery Results in High Rates of Clinically Significant Radionecrosis and Dysregulation of Aquaporin-4.
Stumpf PK; Cittelly DM; Robin TP; Carlson JA; Stuhr KA; Contreras-Zarate MJ; Lai S; Ormond DR; Rusthoven CG; Gaspar LE; Rabinovitch R; Kavanagh BD; Liu A; Diamond JR; Kabos P; Fisher CM
Clin Cancer Res; 2019 Jul; 25(13):3946-3953. PubMed ID: 30940654
[TBL] [Abstract][Full Text] [Related]
7. Central neurotoxicity induced by trastuzumab emtansine (T-DM1): a case report.
Papageorgiou GI; Symeonidis DG; Tsakatikas SA; Liatsos AD; Douglas KAA; Douglas VP; Moschos MM; Kosmas C
Anticancer Drugs; 2021 Nov; 32(10):1146-1149. PubMed ID: 34232951
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience.
Bahçeci A; Paydaş S; Ak N; Ferhatoğlu F; Saip PM; Seydaoğlu G; Bilici M; Şimşek M; Tekin SB; Çalikuşu Z; Yavuz S; Şahin AB; Çubukçu E; Evrensel T; Değirmencioğlu S; Demiray AG; Yumuk PF; Alan Ö; Çikman Dİ; Demirelli FH; Köstek O; Gökyer A; Doğan M; Bal Ö; Çakar B; Gökmen E; Yamaç D; Korkmaz T; Aliyev A; Keskin Ö; Urvay S; Büyükşimşek M; Karadeniz C; Yildiz B; Çinkir HY; Demir H; Beypinar İ; Karaçin C; Eser K; Baykara M; Kiliçkap S; Okutur K; Bulut G; Alkan A; Arpaci E; Pilanci KN; Demir A; Işik D; Yildirim N
Cancer Invest; 2021; 39(6-7):473-481. PubMed ID: 34014777
[TBL] [Abstract][Full Text] [Related]
9. T-DM1-induced thrombocytopenia in breast cancer patients: New perspectives.
Liu F; Ke J; Song Y
Biomed Pharmacother; 2020 Sep; 129():110407. PubMed ID: 32570117
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant Trastuzumab Emtansine (T-DM1) and Concurrent Radiotherapy for Residual Invasive HER2-positive Breast Cancer: Single-center Preliminary Results.
Zolcsák Z; Loirat D; Fourquet A; Kirova YM
Am J Clin Oncol; 2020 Dec; 43(12):895-901. PubMed ID: 33027084
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors of ado-trastuzumab emtansine treatment in patients with metastatic HER-2 positive breast cancer.
Tataroglu Ozyukseler D; Basak M; Ay S; Koseoglu A; Arıcı S; Oyman A; Sürmeli H; Turan M; Turan N; Odabaş H; E Yıldırım M
J Oncol Pharm Pract; 2021 Apr; 27(3):547-554. PubMed ID: 32423326
[TBL] [Abstract][Full Text] [Related]
12. T-DM1 for residual, invasive, HER2-positive breast cancer.
Burki TK
Lancet Oncol; 2019 Jan; 20(1):e13. PubMed ID: 30555022
[No Abstract] [Full Text] [Related]
13. Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer.
Pondé N; Ameye L; Lambertini M; Paesmans M; Piccart M; de Azambuja E
Eur J Cancer; 2020 Feb; 126():65-73. PubMed ID: 31923729
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of pyridostigmine (Mestinon) in the relief of patients with epiphora.
Yazicioglu T; Oklar M; İnan R
Photodiagnosis Photodyn Ther; 2023 Mar; 41():103240. PubMed ID: 36592783
[TBL] [Abstract][Full Text] [Related]
15. Safety of trastuzumab after trastuzumab emtansine-induced nodular regenerative hyperplasia: A case report.
Hassan C; Correal F; Vézina G; Yelle L; Adam JP
J Oncol Pharm Pract; 2020 Oct; 26(7):1780-1784. PubMed ID: 32192389
[TBL] [Abstract][Full Text] [Related]
16. Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel.
Esmaeli B; Amin S; Valero V; Adinin R; Arbuckle R; Banay R; Do KA; Rivera E
J Clin Oncol; 2006 Aug; 24(22):3619-22. PubMed ID: 16877729
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer.
Yeo W; Luk MY; Soong IS; Yuen TY; Ng TY; Mo FK; Chan K; Wong SY; Tsang J; Leung C; Suen JJ; Ngan RK
Hong Kong Med J; 2018 Feb; 24(1):56-62. PubMed ID: 29326401
[TBL] [Abstract][Full Text] [Related]
18. Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer.
Esmaeli B; Hortobagyi GN; Esteva FJ; Booser D; Ahmadi MA; Rivera E; Arbuckle R; Delpassand E; Guerra L; Valero V
Ophthalmology; 2002 Jun; 109(6):1188-91. PubMed ID: 12045065
[TBL] [Abstract][Full Text] [Related]
19. Clinical and radiologic lacrimal testing in patients with epiphora.
Guzek JP; Ching AS; Hoang TA; Dure-Smith P; Llaurado JG; Yau DC; Stephenson CB; Stephenson CM; Elam DA
Ophthalmology; 1997 Nov; 104(11):1875-81. PubMed ID: 9373120
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of trastuzumab emtansine (TDM-1) in a patient on hemodialysis for renal failure.
González AF; Garcia PE; Gastaldo AS; Simón IS; Boffil JS; Borrego MR
Cancer Treat Res Commun; 2021; 27():100314. PubMed ID: 33545569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
